BARGAGLI, ELENA
 Distribuzione geografica
Continente #
EU - Europa 16.165
NA - Nord America 14.527
AS - Asia 2.548
SA - Sud America 181
AF - Africa 118
OC - Oceania 33
Continente sconosciuto - Info sul continente non disponibili 5
Totale 33.577
Nazione #
US - Stati Uniti d'America 14.389
IT - Italia 3.972
GB - Regno Unito 3.272
IE - Irlanda 2.945
SE - Svezia 1.302
RU - Federazione Russa 1.276
CN - Cina 1.175
FR - Francia 814
UA - Ucraina 757
DE - Germania 745
SG - Singapore 695
FI - Finlandia 475
VN - Vietnam 184
ES - Italia 172
BR - Brasile 137
CA - Canada 121
IN - India 121
CZ - Repubblica Ceca 97
CI - Costa d'Avorio 83
NL - Olanda 66
HK - Hong Kong 62
TR - Turchia 56
AT - Austria 47
BE - Belgio 40
IR - Iran 35
JP - Giappone 32
AU - Australia 29
KR - Corea 25
PL - Polonia 25
PH - Filippine 20
PT - Portogallo 20
PK - Pakistan 18
CH - Svizzera 17
RO - Romania 14
DK - Danimarca 13
GR - Grecia 13
UZ - Uzbekistan 13
AE - Emirati Arabi Uniti 12
BG - Bulgaria 12
AZ - Azerbaigian 11
LT - Lituania 11
MA - Marocco 11
PE - Perù 11
BD - Bangladesh 9
KZ - Kazakistan 9
LV - Lettonia 9
AR - Argentina 8
CL - Cile 8
IL - Israele 8
LK - Sri Lanka 8
KG - Kirghizistan 7
MK - Macedonia 7
NG - Nigeria 7
CO - Colombia 6
EE - Estonia 6
EG - Egitto 6
HU - Ungheria 6
JM - Giamaica 6
LU - Lussemburgo 6
MX - Messico 6
NO - Norvegia 6
SA - Arabia Saudita 6
ZA - Sudafrica 6
AM - Armenia 5
EC - Ecuador 5
EU - Europa 5
ID - Indonesia 5
LA - Repubblica Popolare Democratica del Laos 5
GE - Georgia 4
IS - Islanda 4
JO - Giordania 4
NZ - Nuova Zelanda 4
AL - Albania 3
BO - Bolivia 3
BY - Bielorussia 3
CY - Cipro 3
HR - Croazia 3
PA - Panama 3
RS - Serbia 3
CR - Costa Rica 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
TN - Tunisia 2
TW - Taiwan 2
BH - Bahrain 1
BN - Brunei Darussalam 1
DZ - Algeria 1
GA - Gabon 1
IQ - Iraq 1
KH - Cambogia 1
KW - Kuwait 1
LB - Libano 1
MD - Moldavia 1
MM - Myanmar 1
MY - Malesia 1
NP - Nepal 1
PY - Paraguay 1
SC - Seychelles 1
SI - Slovenia 1
Totale 33.574
Città #
Southend 2.999
Dublin 2.907
Fairfield 2.048
Chandler 1.408
Santa Clara 1.260
Ashburn 1.134
Woodbridge 875
Siena 771
Seattle 736
Houston 718
Wilmington 690
Cambridge 623
Jacksonville 579
Singapore 507
Princeton 469
Ann Arbor 388
Lastra a Signa 349
Helsinki 346
Beijing 266
Milan 262
Florence 242
New York 226
Dong Ket 177
Nanjing 177
Boardman 149
San Diego 145
Dearborn 138
Moscow 137
Shanghai 137
Rome 132
Munich 131
San Mateo 126
Málaga 118
Fremont 95
London 91
Abidjan 83
Nanchang 73
Los Angeles 68
Brno 66
Menlo Park 55
Nuremberg 52
Shenyang 50
Ottawa 49
Washington 46
Gavirate 41
Catania 40
Dallas 40
Brussels 39
Hong Kong 39
Norwalk 38
Guangzhou 37
Izmir 36
Chicago 34
Hebei 33
Lappeenranta 33
Redwood City 32
Hangzhou 31
Changsha 30
Toronto 30
Vienna 30
Kunming 29
Naples 29
Olomouc 28
San Francisco 27
Tianjin 27
Frankfurt am Main 26
Jinan 26
Tarazona 26
Jiaxing 25
Agliana 21
Zhengzhou 21
Newark 20
Padova 20
Gießen 19
Bologna 18
Brescia 18
Düsseldorf 18
Hefei 16
Livorno 16
Prato 15
Seongnam 15
Venezia 15
Zanjan 15
Arezzo 14
Genoa 14
Lancaster 14
Ningbo 14
Paris 14
Chianciano Terme 13
Clifton 13
North Bergen 13
Pisa 13
Stockholm 13
Bangalore 12
Central 12
Sofia 12
Warsaw 12
Zurich 12
Amsterdam 11
Hyderabad 11
Totale 23.368
Nome #
La chitotriosidasi: un sensibile biomarker di sarcoidosi 974
Towards a functional proteomics approach to the comprehension of idiopathic pulmonary fibrosis, sarcoidosis, systemic sclerosis and pulmonary Langerhans cell histiocytosis 314
Cytokine modulators in the treatment of sarcoidosis 252
Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis 233
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 217
Alveolar concentration of nitric oxide as a prognostic biomarker in idiopathic pulmonary fibrosis 209
Gorham-Stout disease management during pregnancy 206
Antirheumatic agents in covid-19: is IL-6 the right target? 206
Bronchoalveolar lavage proteomic analysis in pulmonary fibrosis associated with systemic sclerosis: S100A6 and 14-3-3ε as potential biomarkers 202
Peripheral biomarkers' panel for severe COVID-19 patients 202
Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6 199
A system biology study of BALF from patients affected by idiopathic pulmonary fibrosis (IPF) and healthy controls 197
Exhaled nitric oxide in interstitial lung diseases 193
Idiopathic pulmonary fibrosis a rare disease with severe bone fragility 191
Chitotriosidase and soluble IL-2 receptor: comparison of two markers of sarcoidosis severity 188
Increased Risk of Atherosclerosis in Patients with Sarcoidosis 188
Familial pulmonary fibrosis: Clinical and radiological characteristics and progression analysis in different high resolution-CT patterns 185
Diagnosis of idiopathic pulmonary fibrosis by virtual means using “IPFdatabase”- a new software 185
Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib 181
Elevated level of Galectin-1 in bronchoalveolar lavage of patients with idiopathic pulmonary fibrosis 180
Pleuroparenchymal fibroelastosis (PPFE) associated with giant cell arteritis: A coincidence or a novel phenotype? 178
Pulmonary hypertension in idiopathic pulmonary fibrosis: prevalence and clinical progress 174
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males 174
Combined sarcoidosis and idiopathic pulmonary fibrosis (CSIPF): A novel disease phenotype? 172
Mortality on the Waiting List for Lung Transplantation in Patients with Idiopathic Pulmonary Fibrosis: A Single-Centre Experience 171
Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease 171
The effect of cigarette smoking on bronchoalveolar lavage protein profiles from patients with different interstitial lung diseases 170
Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study 169
Antithrombin III as predictive indicator of survival in IPF patients treated with Nintedanib: a preliminary study 169
Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males 169
Rituximab Therapy in Interstitial Lung Disease associated with Rheumatoid Arthritis 167
Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline 167
Harnessing the role of HDAC6 in Idiopathic Pulmonary Fibrosis: design, synthesis, structural analysis, and biological evaluation of potent inhibitors 165
Proteome Characterization of BALF Extracellular Vesicles in Idiopathic Pulmonary Fibrosis: Unveiling Undercover Molecular Pathways 165
Serum chitotriosidase levels in patients with allergic and non-allergic asthma 164
Quality of life, anxiety and depression in Sarcoidosis 161
Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis 158
Trace metals in fluids lining the respiratory system of patients with idiopathic pulmonary fibrosis and diffuse lung diseases 158
The analysis of tryptase in serum of sarcoidosis patients 157
Serum concentrations of Krebs von den Lungen-6 in different COVID-19 phenotypes 157
NK and NKT-like cells in granulomatous and fibrotic lung diseases 156
Phenotypes of organ involvement in sarcoidosis 156
Serum analysis of coagulation factors in IPF and NSIP 155
Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy 155
Fibrotic lung toxicity induced by cytotoxic drugs, radiation and immunotherapy in patients treated for lung cancer 152
Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension 152
Tryptase concentrations in bronchoalveolar lavage from patients with chronic eosinophilic pneumonia 151
Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes 150
Airway-Centered Pleuroparenchymal Fibroelastosis Associated with Non-Necrotizing Granulomas: A Rare New Entity 149
Oxidative stress in the pathogenesis of diffuse lung diseases: a review 148
Prognostic bioindicators in severe COVID-19 patients 148
Sarcoidosis: a review for the internist 148
Chromosome 5 inversion in two siblings, one with Klinefelter syndrome and systemic sclerosis, the other with rheumatoid arthritis 147
Fibrotic Lung Toxicity Induced by Hydroxycarbamide 147
COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs 147
Ceruloplasmin and oxidative stress in severe eosinophilic asthma patients treated with Mepolizumab and Benralizumab 147
Carbonylated proteins in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis 145
null 145
Serum levels of chitotriosidase as a marker of disease activity and clinical stage in sarcoidosis. 144
Sarcoidosis with upper respiratory tract involvement 143
null 143
null 142
A genome-wide association study reveals evidence of association with sarcoidosis at 6p12.1 141
Serum amyloid A in patients with idiopathic pulmonary fibrosis 141
Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features 141
Calgranulin B (S100A9) levels in bronchoalveolar lavage fluid of patients with interstitial lung diseases. 140
Research highlights from the 2018 ERS International Congress: interstitial lung diseases 140
Extracorporeal Photopheresis in Lung Transplantation 140
Analysis of macrophage migration inhibitory factor (MIF) in patients with idiopathic pulmonary fibrosis 139
Atypical HRCT manifestations of pulmonary sarcoidosis 139
Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre 139
A first update on mapping the human genetic architecture of COVID-19 138
Calgranulin B (S100A9/MRP14): a Key molecule in idiopathic pulmonary fibrosis? 138
Analysis of trace elements in bronchoalveolar lavage of patients with diffuse lung diseases 138
Serial KL-6 measurements in COVID-19 patients 138
Impact of interstitial lung disease on short-term and long-term survival of patients undergoing surgery for non-small cell lung cancer: anlysis of risk factors. 134
Proteomic investigation of pulmonary sarcoidosis 134
Omalizumab treatment in Samter's triad: case series and review of the literature 134
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 133
Controversial role of RAGE in the pathogenesis of idiopathic pulmonary fibrosis 132
Incidence and risk factors for respiratory tract bacterial colonization and infection in lung transplant recipients 132
Human Chitotriosidase: a sensitive biomarker of sarcoidosis 131
Assessment of cardiac involvement in sarcoidosis by echocardiography 131
Chitotriosidase activity in the serum of patients with sarcoidosis and pulmonary tuberculosis 131
Serum KL-6 concentrations as a novel biomarker of severe COVID-19 131
Proteome analysis of bronchoalveolar lavage in lung diseases 130
Chitotriosidase activity in patients with interstitial lung disesaes 128
Coronavirus HKU 1 infection with bronchiolitis, pericardial effusion and acute respiratory failure in obese adult female 128
Systematic review and metanalysis of oncomarkers in ipf patients and serial changes of oncomarkers in a prospective italian real-life case series 128
Adiponectin and leptin levels in idiopathic pulmonary fibrosis: A new method for BAL and serum assessment 128
Alveolar nitric oxide is related to periostin levels in idiopathic pulmonary fibrosis 127
SARS-CoV-2 in pleural fluid in a kidney transplant patient 127
Concentrations of major elements and mercury in unstimulated human saliva 126
Severe COVID-19 in hospitalized carriers of single CFTR pathogenic variants 126
Idiopathic pulmonary fibrosis [Fibrosi polmonare idiopatica] 125
The Role of Urinary Calcium and Chitotriosidase in a Cohort of Chronic Sarcoidosis Patients 125
The pathogenetic mechanisms of cough in idiopathic pulmonary fibrosis 125
Gardening in greenhouses as a risk factor for silicosis. 124
Immunoglobulin replacement therapy for yellow nail syndrome 124
BAL biomarkers’ panel for differential diagnosis of interstitial lung diseases 124
Totale 16.538
Categoria #
all - tutte 139.738
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 139.738


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.760 0 0 0 0 0 0 0 517 371 381 160 331
2020/20215.372 198 503 235 694 365 656 308 662 479 363 395 514
2021/20224.341 316 582 360 287 213 151 188 198 180 520 472 874
2022/20235.624 415 584 703 683 413 1.028 359 461 440 198 208 132
2023/20245.384 213 125 490 257 289 1.252 1.617 217 60 174 175 515
2024/20255.859 675 511 1.248 628 1.372 595 493 337 0 0 0 0
Totale 34.850